Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details) - Segments Information

v3.20.1
SEGMENT INFORMATION (Details) - Segments Information - USD ($)
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Oct. 31, 2019
Net loss:      
Net Loss $ (2,616,575) $ (4,966,609)  
Total operating costs and expenses 2,629,869 4,983,728  
Less non-cash share-based compensation (1,021,334) (2,750,164)  
Operating costs and expenses excluding non-cash share-based compensation 1,608,535 2,233,564  
Total assets:      
Total Assets 6,163,951   $ 6,293,693
Operating Segments [Member] | Cancer Diagnostics [Member]      
Net loss:      
Net Loss (1,790,646) (1,804,354)  
Operating costs and expenses excluding non-cash share-based compensation 1,163,924 759,534  
Total assets:      
Total Assets 4,411,569   2,921,784
Operating Segments [Member] | Cancer Therapeutics [Member]      
Net loss:      
Net Loss (825,929) (2,487,285)  
Operating costs and expenses excluding non-cash share-based compensation 444,611 800,791  
Total assets:      
Total Assets 1,604,596   2,872,341
Operating Segments [Member] | Patent Licensing [Member]      
Net loss:      
Net Loss (674,970)  
Operating costs and expenses excluding non-cash share-based compensation $ 673,239  
Total assets:      
Total Assets $ 147,786   $ 499,568